The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
In a phase II trial reported in the Journal of Clinical Oncology, Weiss et al evaluated whether the combination of pembrolizumab and bevacizumab was active in patients with previously untreated melano...
The ASCO Post
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Despite declines in tobacco use, adults with disabilities had higher usage rates. Differences in use across cumulative disabilities persisted or worsened, the study found.
Herpes entering through the nose smells like trouble for the brain. Mangos may have a seat at the metabolic table. And humans don't understand their dogs as much as they think they do. We dive into these studies and more.